



Introducing the **First FDA** **Conditionally Approved** Innovative Solution for Acute Canine Pancreatitis



Scan QR to view full
PANOQUELL®-CA1
prescribing information.




Want to learn more
about PANOQUELL®-CA1?
Scan QR code to earn 3
hours of free CE.*

User Safety Warnings: Not for use in humans. Keep this medication out of reach of children. Limited data is available on the potential teratogenic effects of fuzapladib.

In case of accidental self-injection, skin contact, eye exposure, or accidental ingestion refer to the package insert.

To obtain a Safety Data Sheet, report suspected adverse drug experiences, or for technical assistance, contact Ceva Animal Health at 1-800-999-0297.

For additional information about reporting adverse drug experiences for animal drugs, contact FDA at 1-888-FDA-VEITS or at www.fda.gov/reportanimalae.

 **PANOQUELL®-CA1**
(fuzapladib sodium for injection)
14 mg fuzapladib sodium per vial
4 mg/mL when reconstituted

For intravenous use in dogs only.
Reconstitute before using.

PANOQUELL®-CA1 is a leukocyte function-associated antigen 1 (LFA-1) activation inhibitor.

Indication: For the management of clinical signs associated with acute onset of pancreatitis in dogs.

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-567. It is a violation of Federal law to use this product other than as directed in the labeling.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.



Take the "ITIS" out of pancreatitis

PANOQUELL®-CA1

(fuzapladib sodium for injection)

*Available through May 26, 2023.

PANOQUELL®-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-567. It is a violation of Federal Law to use this product other than as directed in the labeling. PANOQUELL® is a registered trademark of Ishihara Sangyo Kaisha, Ltd.



©2023 Ceva Animal Health, LLC.

PAN-108-23v1